Citations (138)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
John Gubatan, Kian Keyashian, Samuel J S Rubin, Jenny Wang, Cyrus A Buckman & Sidhartha Sinha. (2021) Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clinical and Experimental Gastroenterology 14, pages 333-342.
Read now
Read now
Adithya Kannan, Mychael Delgardo, William Pennington-FitzGerald, Enoch X. Jiang, Brandon R. Christophe & E Sander Connolly$suffix/text()$suffix/text(). (2021) Pharmacological management of cerebral ischemia in the elderly. Expert Opinion on Pharmacotherapy 22:7, pages 897-906.
Read now
Read now
Nourollah Ramroodi, Masood Khani, Zohre Ganjali, Mohammad Reza Javan, Nima Sanadgol, Roghayeh Khalseh, Hadi Ravan, Ehsan Sanadgol & Mohammad Abdollahi. (2015) Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis. Immunological Investigations 44:7, pages 694-712.
Read now
Read now
Michael D Wiese, Vijayaprakash Suppiah & Catherine O’Doherty. (2014) Metabolic and safety issues for multiple sclerosis pharmacotherapy – opportunities for personalised medicine. Expert Opinion on Drug Metabolism & Toxicology 10:8, pages 1145-1159.
Read now
Read now
Pietro Iaffaldano, Guglielmo Lucchese & Maria Trojano. (2011) Treating multiple sclerosis with natalizumab. Expert Review of Neurotherapeutics 11:12, pages 1683-1692.
Read now
Read now
Douglas R Jeffery, Clyde E Markowitz, Anthony T Reder, Bianca Weinstock-Guttman & Kathy Tobias. (2011) Fingolimod for the treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics 11:2, pages 165-183.
Read now
Read now
Ashley Bivins, Karolyn Hou, Nana Ayesu, Brian Ellsworth$suffix/text()$suffix/text(), Susan Montenegro, Xiao Tu, Cynthia Boyle, Thomas Dowling & Fadia T Shaya. (2010) Clinical evaluation of natalizumab for formulary consideration. Expert Opinion on Biological Therapy 10:8, pages 1279-1287.
Read now
Read now
Justin Bakhshai, Raymond Bleu-Lainé, Miah Jung, Jeanne Lim, Christian Reyes, Linda Sun, Charmaine Rochester & Fadia T. Shaya. (2010) The cost effectiveness and budget impact of natalizumab for formulary inclusion. Journal of Medical Economics 13:1, pages 63-69.
Read now
Read now
Evelyn Chiao & Kellie Meyer. (2009) Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Current Medical Research and Opinion 25:6, pages 1445-1454.
Read now
Read now
Bianca Weinstock-Guttman, Murali Ramanathan & Robert Zivadinov. (2008) Interferon-β treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy 8:9, pages 1435-1447.
Read now
Read now
Mathias Buttmann & Peter Rieckmann. (2008) Treating multiple sclerosis with monoclonal antibodies. Expert Review of Neurotherapeutics 8:3, pages 433-455.
Read now
Read now
Michael Hutchinson. (2007) Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management 3:2, pages 259-268.
Read now
Read now
Paul O’Connor. (2007) Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy 7:1, pages 123-136.
Read now
Read now
Joseph R. Berger & Sidney Houff. (2006) Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurological Research 28:3, pages 299-305.
Read now
Read now
Norman J Kachuck. (2005) Challenges and opportunities: what we are learning from the clinical natalizumab experience. Expert Review of Neurotherapeutics 5:5, pages 605-615.
Read now
Read now
Jack Burks. (2005) Interferon-β1b for multiple sclerosis. Expert Review of Neurotherapeutics 5:2, pages 153-164.
Read now
Read now
Articles from other publishers (122)
Longfei Wu, Haiqing Song, Chi Zhang, Anxin Wang, Bowei Zhang, Chiyu Xiong, Xianbo Zhuang, Yingzhuo Zang, Chenghao Li, Qi Fang, Chuanqiang Qu, Lihua Wang, Mei Zhang, Hao Li, Xiaoli Wang, Yanan Li, Lei Xia, Zhigang Yao, Zhi Nie, Ying Gao & Xunming Ji. (2023)
Efficacy and Safety of
Panax notoginseng
Saponins in the Treatment of Adults With Ischemic Stroke in China
. JAMA Network Open 6:6, pages e2317574.
Crossref
Crossref
Fabian Foettinger, Georg Pilz, Peter Wipfler, Andrea Harrer, Jan Marco Kern, Eugen Trinka & Tobias Moser. (2023) Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders—A Pilot Study. International Journal of Molecular Sciences 24:7, pages 6552.
Crossref
Crossref
Daniela Gallo, Denisa Baci, Natasa Kustrimovic, Nicola Lanzo, Bohdan Patera, Maria Laura Tanda, Eliana Piantanida & Lorenzo Mortara. (2023) How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases?. International Journal of Molecular Sciences 24:5, pages 4689.
Crossref
Crossref
Giuseppe Magro, Stefania Barone, Federico Tosto, Antonio De Martino, Domenico Santange lo, Lucia Manzo, Angelo Pascarella, Pietro Bruno, Marilisa Pasquale, Antonio Gambardella & Paola Valentino. (2022) Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic. Journal of Neurology 270:2, pages 595-600.
Crossref
Crossref
John F Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen, Douglas L Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Karen Smirnakis, Shan Xiao, George Kong, Robert Kuhelj, Nolan Campbell, Anneke van der Walt, Christopher Dwyer, Katherine Buzzard, Judith Spies, John Parratt, Vincent van Pesch, Barbara Willekens, Gaetano Perrotta, Emmanuel Bartholomé, Francois Grand'Maison, Francois Jacques, Paul Giacomini, Reza Vosoughi, Jean-Marc Girard, Jerome de Seze, Christine Lebrun Frenay, Aurelie Ruet, David-Axel Laplaud, Gerd Reifschneider, Bert Wagner, Sebastian Rauer, Refik Pul, Maria Seipelt, Achim Berthele, Luisa Klotz, Boris-Alexander Kallmann, Friedemann Paul, Anat Achiron, Giacomo Lus, Diego Centonze, Francesco Patti, Luigi Grimaldi, Raymond Hupperts, Stephan Frequin, Jiske Fermont, Sara Eichau Madueno, Ana Maria Alonso Torres, Lucienne Costa-Frossard França, Jose Eustasio Meca-Lallana, Luis Brieva Ruiz, Owen Pearson, David Rog, Nikolaos Evangelou, Azza Ismail, Ellen Lathi, Edward Fox, Thomas Leist, Jacob Sloane, Gregory Wu, Bhupendra Khatri, Brian Steingo, Ben Thrower, Mark Gudesblatt, Jonathan Calkwood, Daniel Bandari, John Scagnelli, Christopher Laganke, Derrick Robertson, Lucas Kipp, Martin Belkin, Stanley Cohan, Lawrence Goldstick, Ardith Courtney, Wendy Vargas, Andrew Sylvester, Jayshri Srinivasan, Meena Kannan, Maryann Picone, Jeffrey English, Salvatore Napoli, Roumen Balabanov, Islam Zaydan, Jacqueline Nicholas, Jeffrey Kaplan, Fred Lublin, Emily Riser, Tamara Miller, Enrique Alvarez, Sibyl Wray, Jeffrey Gross, Siddharama Pawate, Carrie Hersh, Lucas McCarthy, Heidi Crayton & Jennifer Graves. (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. The Lancet Neurology 21:7, pages 608-619.
Crossref
Crossref
Carla Rodriguez-Mogeda, Sabela Rodríguez-Lorenzo, Jiji Attia, Jack van Horssen, Maarten E. Witte & Helga E. de Vries. (2022) Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis. Biomolecules 12:6, pages 800.
Crossref
Crossref
Zoë YGJ van Lierop, Luuk Wieske, Marleen JA Koel-Simmelink, Madhurima Chatterjee, Iris Dekker, Cyra E Leurs, Eline AJ Willemse, Bastiaan Moraal, Frederik Barkhof, Filip Eftimov, Bernhard MJ Uitdehaag, Joep Killestein & Charlotte E Teunissen. (2021) Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Multiple Sclerosis Journal 28:1, pages 102-110.
Crossref
Crossref
Julian Perneczky & Johann Sellner. (2022) Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience. Journal of Central Nervous System Disease 14, pages 117957352211354.
Crossref
Crossref
Saara Kaviany & Carrie L. Kitko. (2021) The role of biomarkers in risk stratification, treatment and outcome in acute GVHD. Current Opinion in Hematology 28:6, pages 401-407.
Crossref
Crossref
Dardiotis Efthimios, Karachalios Georgios, Alexopoulou Antonia, Gourgioti Rania & Evangelopoulos Maria-Eleutheria. (2021) Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’. Clinical Drug Investigation 41:10, pages 865-874.
Crossref
Crossref
Panagiotis Karanasios, Georgios Karachalios, Rania Gourgioti, Antonia Alexopoulou & Vasileios Mastorodemos. (2021) Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study ‘TOPICS greece’. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7:3, pages 205521732110358.
Crossref
Crossref
Natasha Kekre, Haesook T. Kim, Julia Hofer, Vincent T. Ho, John Koreth, Philippe Armand, Sarah Nikiforow, Mahasweta Gooptu, Rizwan Romee, Edwin P. Alyea, Prashant Nageshwar, Brett Glotzbecker, Areej El-Jawahri, Zachariah DeFilipp, Robert J. Soiffer, Joseph H. Antin, Yi-Bin Chen & Corey Cutler. (2020) Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplantation 56:5, pages 1006-1012.
Crossref
Crossref
Stefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, Elisabetta Signoriello, Giacomo Lus, Simona Bonavita, Gianmarco Abbadessa, Luigi Lavorgna, Giorgia Teresa Maniscalco, Erica Curti, Lorena Lorefice, Eleonora Cocco, Viviana Nociti, Massimiliano Mirabella, Damiano Baroncini, Giorgia Mataluni, Doriana Landi, Martina Petruzzo, Roberta Lanzillo, Ilaria Gandoglia, Alice Laroni, Rita Frangiamore, Arianna Sartori, Paola Cavalla, Gianfranco Costantini, Ruggero Capra, Maria Pia Sormani & Marinella Clerico. (2021) MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences 424, pages 117385.
Crossref
Crossref
Javier Riancho, Sonia Setien, Jose Ramón Sánchez de la Torre, Marta Torres-Barquin, Mercedes Misiego, José Luis Pérez, Tamara Castillo-Triviño, Cristina Menéndez-García & Manuel Delgado-Alvarado. (2021) Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study. Frontiers in Immunology 12.
Crossref
Crossref
Nicolae Moise & Avner Friedman. (2021) A mathematical model of the multiple sclerosis plaque. Journal of Theoretical Biology 512, pages 110532.
Crossref
Crossref
Ih Chang, Kumar Kandadi Muralidharan, Nolan Campbell & Pei‐Ran Ho. (2020) Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing. The Journal of Clinical Pharmacology 61:3, pages 339-348.
Crossref
Crossref
Oliver Findling & Johann Sellner. (2021) Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?. Drug Discovery Today 26:2, pages 416-428.
Crossref
Crossref
Mika Takarada-Iemata & Osamu Hori. (2021) Astrocytes in the pathogenesis of multiple sclerosis多発性硬化症の病態を修飾するアストロサイト. Folia Pharmacologica Japonica 156:4, pages 230-234.
Crossref
Crossref
Aristos Aristodimou, Athos Antoniades, Efthimios Dardiotis, Eleni Loizidou, George Spyrou, Christina Votsi, Christodoulou Kyproula, Marios Pantzaris, Nikolaos Grigoriadis, Georgios Hadjigeorgiou, Theodoros Kyriakides & Constantinos Pattichi. (2021) A Framework for Efficient N-Way Interaction Testing in Case/Control Studies With Categorical Data. IEEE Open Journal of Engineering in Medicine and Biology 2, pages 256-262.
Crossref
Crossref
Surojit Paul & Eduardo Candelario-Jalil. (2021) Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Experimental Neurology 335, pages 113518.
Crossref
Crossref
Michelle Naughton, Jill Moffat, George Eleftheriadis, Nira de la Vega Gallardo, Andrew Young, John Falconer, Kristen Hawkins, Ben Pearson, Bernard Perbal, Andrew Hogan, Paul Moynagh, Sam Loveless, Neil P. Robertson, Bruno Gran, Rachael Kee, Stella Hughes, Gavin McDonnell, Owain Howell & Denise C. Fitzgerald. (2020) CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17:1.
Crossref
Crossref
Clara Grazia Chisari, Luigi Maria Grimaldi, Giuseppe Salemi, Paolo Ragonese, Pietro Iaffaldano, Simona Bonavita, Maddalena Sparaco, Marco Rovaris, Alessia D'Arma, Alessandra Lugaresi, Maria Teresa Ferrò, Paola Grossi, Alessia Di Sapio, Eleonora Cocco, Franco Granella, Erica Curti, Vito Lepore, Maria Trojano & Francesco Patti. (2020) Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 91:12, pages 1297-1303.
Crossref
Crossref
Asma Beldi-Ferchiou, Abir Wahab, Matthieu Duchmann, Jérôme Hodel, Ivania Patry, Marie-Hélène Delfau-Larue, Valérie Molinier-Frenkel & Alain Créange. (2020) High effector-memory CD8+ T-cell levels correlate with high PML risk in natalizumab-treated patients. Multiple Sclerosis and Related Disorders 46, pages 102470.
Crossref
Crossref
Mitchell S.V. ElkindRoland VeltkampJoan MontanerS. Claiborne JohnstonAneesh B. SinghalKyra BeckerMaarten G. LansbergWeihua TangRachna KasliwalJacob Elkins. (2020) Natalizumab in acute ischemic stroke (ACTION II). Neurology 95:8.
Crossref
Crossref
Lana Zhovtis RyersonXiaochun LiJudith D. Goldberg, Tamara HoytAngel ChristensenRyan R. MetzgerIlya Kister & John Foley. (2020) Pharmacodynamics of natalizumab extended interval dosing in MS. Neurology Neuroimmunology & Neuroinflammation 7:2.
Crossref
Crossref
Devon S Conway, Carrie M Hersh, Haleigh C Harris & Le H Hua. (2020) Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:1, pages 205521732090248.
Crossref
Crossref
Lana Zhovtis Ryerson & Eugene O. Major. (2020) Natalizumab related progressive multifocal leukoencephalopathy. Drug Discovery Today: Disease Models 32, pages 13-19.
Crossref
Crossref
Yifei Dong & V. Wee Yong. (2019) When encephalitogenic T cells collaborate with microglia in multiple sclerosis. Nature Reviews Neurology 15:12, pages 704-717.
Crossref
Crossref
J. Daniel Griffin, Jimmy Y. Song, Aric Huang, Alexander R. Sedlacek, Kaitlin L. Flannagan & Cory J. Berkland. (2019) Antigen-specific immune decoys intercept and exhaust autoimmunity to prevent disease. Biomaterials 222, pages 119440.
Crossref
Crossref
Zoé L.E. van Kempen, Djoeke DoesburgIris DekkerBirgit I. Lissenberg-WitteAnnick de VriesIris A. ClaessenAnja ten BrinkeTheo RispensJoep Killestein. (2019) The natalizumab wearing-off effect. Neurology 93:17.
Crossref
Crossref
Lana Zhovtis RyersonJohn FoleyIh ChangIlya KisterGary Cutter, Ryan R. MetzgerJudith D. Goldberg, Xiaochun LiEvan RiddleKaren SmirnakisRachna KasliwalZheng RenChristophe HotermansPei-Ran HoNolan Campbell. (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93:15.
Crossref
Crossref
I. Dekker, C.E. Leurs, M.H.J. Hagens, Z.L.E. van Kempen, I. Kleerekooper, B.I. Lissenberg-Witte, F. Barkhof, B.M.J. Uitdehaag, L.J. Balk, M.P. Wattjes & J. Killestein. (2019) Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. Multiple Sclerosis and Related Disorders 33, pages 82-87.
Crossref
Crossref
Ebtesam Alshehri & Jeffery A. Cohen. 2019. Emerging Drugs and Targets for Multiple Sclerosis. Emerging Drugs and Targets for Multiple Sclerosis
111
133
.
Efthimios DardiotisElena PanayiotouVasileios SiokasAthina-Maria AloizouKyproula ChristodoulouAndreas HadjisavvasMarios PantzarisNikolaos GrigoriadisGeorgios M. HadjigeorgiouTheodoros Kyriakides. (2019) Gene variants of adhesion molecules predispose to MS: A case-control study. Neurology Genetics 5:1.
Crossref
Crossref
Marco Iannetta, Maria Antonella Zingaropoli, Tiziana Latronico, Ilaria Pati, Simona Pontecorvo, Carla Prezioso, Valeria Pietropaolo, Antonio Cortese, Marco Frontoni, Claudia D’Agostino, Ada Francia, Vincenzo Vullo, Claudio Maria Mastroianni, Grazia Maria Liuzzi & Maria Rosa Ciardi. (2019) Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. Scientific Reports 9:1.
Crossref
Crossref
Yara Dadalti Fragoso, Tarso Adoni, Joseph B. Bidin Brooks, Alessandro Finkelsztejn, Paulo Diniz da Gama, Anderson K. Grzesiuk, Vanessa Daccach Marques, Monica Fiuza K. Parolin, Henry K. Sato, Daniel Lima Varela & Claudia Cristina F. Vasconcelos. (2018) Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children. Neurology and Therapy 7:2, pages 207-232.
Crossref
Crossref
Georgios-Marios Makris, Jonida Mene, Alexandros Fotiou, Vasileia Xyla, Marco-Johannes Battista & Theodoros N. Sergentanis. (2018) Gynecological adverse effects of natalizumab administration: Case report and review of the literature. Multiple Sclerosis and Related Disorders 25, pages 46-49.
Crossref
Crossref
Julián Panés & Azucena Salas. (2018) Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:suppl_2, pages S633-S640.
Crossref
Crossref
Bassem I. Yamout, Mohamad Ali Sahraian, Nabil El Ayoubi, Hani Tamim, Johnny Nicolas, Samia J. Khoury & Maya M Zeineddine. (2018) Efficacy and safety of natalizumab extended interval dosing. Multiple Sclerosis and Related Disorders 24, pages 113-116.
Crossref
Crossref
Maria Trojano, Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, Tim Spelman, Fabio Pellegrini, Yi Chen, Qunming Dong, Harold Koendgen, Shibeshih Belachew, Jorge Correale, Alejandro Caride, Norma H. Deri, Carlos Ballario, Simon Broadley, Chris Kneebone, Michael Barnett, John Pollard, Suzanne Hodgkinson, Allan Kermode, Richard Macdonell, John King, Helmut Butzkueven, Jeannette Lechner-Scott, Noel Saines, Mark Slee, Chris Plummer, Barbara Willekens, Ludo Vanopdenbosch, Shibeshih Belachew, Rémy Phan-Ba, Valérie Delvaux, Veronique Bissay, Jan Debruyne, Danny Decoo, Roeland Crols, Anoek Symons, Guy Nagels, Vincent Van Pesch, Christian Sindic, Benedicte Dubois, Robert Medaer, Marie D'Hooghe, Daniel Guillaume, Eric De Smet, Pierrette Seeldrayers, Andreas Lysandropoulos, Mathieu Vokaer, Karine Geens, Christina Willems, Pierre Denayer, Michel Bureau, Cecile Retif, Michel Dupuis, Olivier Bouquiaux, Patrick Vanderdonckt, William van Landegem, Jo Caekebeke, Erwin Van Ingelghem, Katelijne Peeters, Pascale Gerard, Alain Maertens de Noordhout, Philippe Desfontaines, Etienne Urbain, Inge Declercq, Bart Van Wijmeersch, Erwin Vanroose, Alain Wibail, Emmanuel Barthomolé, Melanie Ursell, Margaret Elizabeth Sweet, David Howse, Draga Jichici, Melad Shawush, Mike Namaka, Anthony Traboulsee, Stan Hashimoto, Raymond Lo, Paul Marchetti, Yves Lapierre, Francois Jacques, Gregg MacLean, Virender Bhan, Pierre Duquette, Bradley Stewart, John Paulseth, Marcelo Kremenchutzky, Galina Vorobeychik, Paul O'Connor, François Grand'Maison, Eva Havrdova, Eva Meluzinová, Martin Valis, Radomír Talab, Pavel Stourac, Olga Zapletalová, Michal Dufek, Vladimíra Sládková, Alena Novotna, Romana Vancurová, Libuse Lhotaková, Jiri Fiedler, Marta Vachova, David Dolezil, Ivana Stetkarova, Adela Rehankova, Petr Psenica, Veronika Ulehlova, Sona Feketova, Ondrej Skoda, Markus Färkkilä, Sarasoja Taneli, Keijo Koivisto, Juha Matti Seppä, Laura Airas, Irina Elovaara, Päivi Hartikainen, Tuula Pirttila, Pierre Louchart, Olivier Ille, Jean philippe Thenint, Etienne Godet, Marcel Maillet Vioud, Renato Colamarino, Michel Gugenheim, Jerome Grimaud, Audrey Kopf, Christophe Billy, Bernard Huttin, Jean paul Borsotti, Philippe Devos, Jean bertin N Kendjuo, Albert Verier, Stephane Chapuis, Nathalie Daluzeau, Gilles Angibaud, Marie-Sylvie Artaud Uriot, François Ziegler, François Sellal, Antoine Moulignier, Isabelle Lavenu, Samir Ismail, Richard Devy, Manuel Suceveanu, Marc Wagner, Sebastien Marcel, Faycal Derouiche, Sohrab Mostoufizadehghalamfarsa, Sophie Delalande, Irene Ruggieri, Catherine Bossu Van Nieuwenhuyse, Chantal Nifle, Basile Ondze, Carmen Gurau Vasilescu, Cyrille Vongsouthi, Marc Coustans, Olivier Anne, Josephine Amevigbe, Jerome Servan, Marc Merienne, Philippe Eck, Stephane Berroir, Philippe Busson, Bruno Barroso, Jean-Marc Larrieu, Catherine Louvet Giendaj, Imad Malkoun, Patrick Hautecoeur, Arnaud Kwiatkowski, Andre Pouliquen, Guillaume Garrigues, Olivier Delerue, Pierric Giraud, Julien Gere, Jean Vaunaize, Olivier Dereeper, Nicolas Seiller, Roger Alsassa, Mihaela Vlaicu, Veronique Neuville, Jean Marc Faucheux, Patricia Bernady, Guy Fanjaud, François Viallet, Michael Schroeter, Sylke Schlemilch-Paschen, Thomas Lange, Kin-Arno Bohr, Klaus Jendroska, Elisabeth Rehkopf, Arnfin Bergmann, Christoph Kleinschnitz, Thomas Postert, Peter Scholz, Uwe Mauz, Hubert Stratmann, Veneta Siefjediers, Martin Prantl, Klaus Gehring, Ruth Zellner, Kathrin Junge, Anton Zellner, Valerina Bacay, Eugen Schlegel, Udo Polzer, Erik Strauss, Andreas Link, Christoph Stenzel, Matthias Freidel, Joachim Drews, Christian Neudert, Frank Schmitz, Joachim Jaeger, Said Masri, Wolfgang Heuberger, Beate Trausch, Oliver Ruhnke, Serena Scarel, Kathlen Bach, Michael Ernst, Harald Landefeld, Nils Richter, Stephan Schmidt, Michaela Krause, Alezander Dressel, Roland Ruth, Kerstin Anvari, Jens Gossling, Christoph Schenk, Oliver Tiedge, Lutz Bode, Hans-Thomas Eder, Oliver Pfeffer, Reinhard Krug, Christoph Lassek, Eberhard Fleischer, Sven Meuth, Luisa Hildegard Klotz, Ines Peglau, Borries Kukowski, Birgit Herting, Kersten Guthke, Jurgen Schierenbeck, Bernd Brockmeier, Holger Albrecht, Matthias Wuttke, Regine Augspach-Hofmann, Stefan Gunther, Martin Redbrake, Christian Franke, Klaus Buchner, Thomas Gratz, Rolf Horn, Frank Doemges, Martin Schreiber, Thomas Brosch, Markus Horn, Matthias Kittlitz, Gabriele Vulturius, Paul Hinse, Rolf Malessa, Stephan Wiehler, Zaza Katsarava, Oliver Kastrup, Ulrich Kausch, Martin Gullekes, Markus Fickinger, Wilhelm Wenzel, Ingolf C. Botefur, Gerd Reifschneider, Sebastian Rauer, Michael Lang, Lutz Harms, Ulrich Eckhardt, Simone Cursiefen, Ralf Linker, Klemens Angstwurm, Judith Haas, Ivo Schuetze, Eva Rohm, H. Stienker-Fisse, Michael Sailer, Johannes Bohringer, Mathias Maurer, Eberhard Bause, Ronald Wersching, Reinhardt Dachsel, Sylke Domke, Frank Hoffman, Bjorn Tackenberg, Kerstin Roch, Uwe Ziebold, Boris Kallmann, Bernhard Buehler, Judith Faiss, Juergen Faiss, Sebastian Schimrigk, Christian Menges, Karl Christian Knop, Wolfgang Koehler, Arno Siever, Johannes Bufler, Georg Gramsl, Benedicta Kuhnler, Matthias Maschke, Florian Stogbauer, Lisa Staude, Florian Bethke, Andreas Bitsch, Arndt D. Harmjanz, Jorg Windsheimer, Bernd C. Kieseier, Ralf Berkenfeld, Hayrettin Tumani, Michael Kirsch, Brigitte Wildemann, Regina Daniels, Klaus Gottwald, Wolfgang-Gerhard Elias, Olaf Hoffmann, Matthias Schwab, Christopher Pilz, Fabian Klostermann, Kerstin Hellwig, Achim Berthele, Antonios Bayas, Daniel Molitor, Christoph Grothe, Bert Wagner, Klimentini Karageorgiou, Dimosthenis Mitsikostas, Antonios Kodounis, Andreas Plaitakis, Alexandros Papadimitriou, Nikolaos Grigoriadis, Nikolaos Vlaikidis, Evaggelos Koutlas, Athanassios Kyritsis, Panagiotis Papathanassopoulos, Nikolaos Makris, Antonios Tavernarakis, Elio Scarpini, Enrico Montanari, Maria Giovanna Marrosu, Maria Trojano, Maria Pia Amato, Mariarosa Rottoli, Alessandra Lugaresi, Ciro Florio, Claudio Gasperini, Luigi Grimaldi, Enrico Millefiorini, Tatiana Koudriavtseva, Franco Perla, Renato Mantegazza, Antonio Bertolotto, Angelo Ghezzi, Sandra Quinones Aguilar, Eli Skromne Eisenberg, Leondardo Llamas Lopez, Rocio Marquez Estudillo, H.M. Schrijver, M.C. Wittebol, J.C. Baart, A.E.L. van Golde, G.J.D. Hengstman, P.H.M. Pop, M. Bos (Geldrop)R. Medaer, Angelique Schyns-Soeterboek, A. van der Zwart, A.J.H. van Diepen, G.A.M. Verheul, W.I.M. Verhagen, M. Bos (Helmond)R.J.G.M. Witjes, L.G.F. Sinnige, E.Th.L. van Munster, E.A.C.M. Sanders, Ron van Dijl, R.M.M. Hupperts, S.T.F.M. Frequin, L.H. Visser, J.M.L. Henselmans, J.W.B. Moll, Rune Midgard, Kjell Morten Myhr, Astrid Edland, Wenche Telstad, Tone Hognestad, Christian Lund, Harald Hovdal, Kaur Kamaljit, Jan Schepel, Roelfien Ida Hogenesch, Stephan Schüler, Francis Odeh, Karl B. Alstadhaug, Olav Korsgaard, Elisabeth Farbu, Teis Barclay Ingvaldsen, Diana Soares (SCO)José Rente, José Manuel Costa Guerra, Armando Morganho, António Leitão, João de Sá, Maria José Sá, Pinto Marques, Mário Veloso, Miguel Viana Baptista, Jarmila Szilasiová, Daniela Copikova-Cudrakova, Lubica Prochazkova, Eleonóra Klimová, Vladimir Donath, Miroslav Brozman, Cristina Ramo, Domingo Pérez Ruiz, Carmen Calles Hernández, María Eugenia Marzo Sola, Roberto Suarez Moro, Jose Antonio Vidal, Ana Belén Caminero Rodríguez, Gisela Martin Ozaeta, Jordi Batlle Nadal, Amaya Alvarez de Arcaya Esquide, Javier Olascoaga Urtaza, Sergio Martínez-Yélamos, Txomin Arbizu, Lluis Ramio i Torrenta, Mike Boggild, Martin Wilson, Adnan Al-Araji, Richard Nicholas, Timothy Harrower, Ian Redmond, Tilo Wolf, Michael Osei-Bonsu, Gordon Mazibrada, David Rog, David Cottrell, Cris Constantinescu, Orla Gray, Mohamed Belhag, Abdullah Shehu, Waqar Rashid & Martin Duddy. (2018) Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders 24, pages 11-19.
Crossref
Crossref
Kelson James Almeida, Raissa Viera Barreto-Soares, Raimundo Nonato Campos-Sousa, Maria Graças Campos-Sousa & Edson Bor-Seng-Shu. (2018) Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis. Multiple Sclerosis Journal 24:7, pages 1002-1004.
Crossref
Crossref
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Kubala Havrdová, Douglas Jeffery, Aaron Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, Emmanuel Bartholomé, Marie D'Hooghe, Massimo Pandolfo, Bart Van Wijmeersch, Virender Bhan, Gregg Blevins, Donald Brunet, Virginia Devonshire, Pierre Duquette, Mark Freedman, François Grand'Maison, François Jacques, Yves Lapierre, Liesly Lee, Sarah Morrow, Michael Yeung, Michal Dufek, Eva Kubala Havrdová, Petr Kanovsky, Ivana Stetkarova, Marika Talabova, Jette Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, Finn Sellebjerg, Laura Airas, Irina Elovaara, Juha-Pekka Eralinna, Taneli Sarasoja, Abdullatif Al Khedr, David Brassat, Bruno Brochet, William Camu, Marc Debouverie, David Laplaud, Christine Lebrun Frenay, Jean Pelletier, Patrick Vermersch, Sandra Vukusi, Karl Baum, Achim Berthele, Juergen Faiss, Peter Flachenecker, Reinhard Hohlfeld, Markus Krumbholz, Christoph Lassek, Mathias Maeurer, Sven Meuth, Tjalf Ziemssen, Orla Hardiman, Christopher McGuigan, Anat Achiron, Dimitrios Karussis, Roberto Bergamaschi, Vincenzo Brescia Morra, Giancarlo Comi, Salvatore Cottone, Luigi Grimaldi, Giovanni Luigi Mancardi, Luca Massacesi, Ugo Nocentini, Marco Salvetti, Elio Scarpini, Patrizia Sola, Gioacchino Tedeschi, Maria Trojano, Mauro Zaffaroni, Stephan Frequin, Raymond Hupperts, Joep Killestein, Hans Schrijver, Ronald Van Dijl, Erik van Munster, Maciej Czarnecki, Wieslaw Drozdowski, Waldemar Fryze, Hanka Hertmanowska, Jan Ilkowski, Anna Kaminska, Gabriela Klodowska-Duda, Maciej Maciejowski, Ewa Motta, Ryszard Podemski, Andrzej Potemkowski, Teresa Rog, Krzysztof Selmaj, Zbigniew Stelmasiak, Adam Stepien, Andrzej Tutaj, Jacek Zaborski, Alexey Boyko, Zanna Chefranova, Evgeny Evdoshenko, Farit Khabirov, Stella Sivertseva, Eduard Yakupov, Jose Carlos Alvarez Cermeño, Antonio Escartin, Oscar Fernandez Fernandez, Antonio Garcia-Merino, Miguel Angel Hernandez Perez, Guillermo Izquierdo Ayuso, José Meca Lallana, Xavier Montalban Gairin, Celia Oreja-Guevara, Albert Saiz Hinarejos, Martin Gunnarsson, Jan Lycke, Claes Martin, Fredrik Piehl, Homayoun Roshanisefat, Peter Sundstrom, Martin Duddy, Bruno Gran, Timothy Harrower, Jeremy Hobart, Raju Kapoor, Martin Lee, Paul Mattison, Richard Nicholas, Owen Pearson, Waqar Rashid, David Rog, Basil Sharrack, Eli Silber, Ben Turner, Anna Williams, John Woolmore, Carolyn Young, Daniel Bandari, Joseph Berger, Ann Camac, Stanley Cohan, Jill Conway, Keith Edwards, Michelle Fabian, Jack Florin, Steven Freedman, Dennis Garwacki, Myla Goldman, Daniel Harrison, Craig Herrman, Deren Huang, Adil Javed, Douglas Jeffery, Stephen Kamin, George Katsamakis, Bhupendra Khatri, Annette Langer-Gould, Sharon Lynch, David Mattson, Tamara Miller, Augusto Miravalle, Harold Moses, Suraj Muley, James Napier, Allen Nielsen, Andrew Pachner, Gabriel Pardo, MaryAnn Picone, Derrick Robertson, Walter Royal, Christopher Sheppard, Ben Thrower, Cary Twyman, Emmanuelle Waubant, Jeanette Wendt, Vijayshree Yadav, Rana Zabad & Greg Zarelli. (2018) Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet Neurology 17:5, pages 405-415.
Crossref
Crossref
Joan Puñet-Ortiz, José Vicente Hervás-García, Aina Teniente-Serra, Antonio Cano-Orgaz, Maria José Mansilla, Bibiana Quirant-Sánchez, Juan Navarro-Barriuso, Marco A. Fernández-Sanmartín, Silvia Presas-Rodríguez, Cristina Ramo-Tello & Eva María Martínez-Cáceres. (2018) Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients. Cytometry Part B: Clinical Cytometry 94:2, pages 327-333.
Crossref
Crossref
Tamara G. Dacoba, Ana Olivera, Dolores Torres, José Crecente-Campo & María José Alonso. (2017) Modulating the immune system through nanotechnology. Seminars in Immunology 34, pages 78-102.
Crossref
Crossref
Chandrashekar Bohra, Lubomir Sokol & Samir Dalia. (2017) Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies. Cancer Control 24:4, pages 107327481772990.
Crossref
Crossref
Tatiana PlavinaKumar Kandadi MuralidharanGeoffrey KuestersDaniel MikolKarleyton EvansMeena SubramanyamIvan NestorovYi ChenQunming DongPei-Ran HoDiogo AmaranteAlison AdamsJerome De SèzeRobert FoxRalf GoldDouglas JefferyLudwig KapposXavier MontalbanBianca Weinstock-GuttmanHans-Peter HartungBruce A.C. Cree. (2017) Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 89:15, pages 1584-1593.
Crossref
Crossref
Kumar Kandadi Muralidharan, Geoffrey Kuesters, Tatiana Plavina, Meena Subramanyam, Daniel D. Mikol, Sreeja Gopal & Ivan Nestorov. (2017) Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis. The Journal of Clinical Pharmacology 57:8, pages 1017-1030.
Crossref
Crossref
Efthimios DardiotisElena PanayiotouAntonios ProvatasKyproula ChristodoulouAndreas HadjisavvasAthos AntoniadesAthanasios LourbopoulosMarios PantzarisNikolaos GrigoriadisGeorgios M. HadjigeorgiouTheodoros Kyriakides. (2017) Gene variants of adhesion molecules act as modifiers of disease severity in MS. Neurology Neuroimmunology & Neuroinflammation 4:4.
Crossref
Crossref
Meena Subramanyam, Joan Lane & Jim Fikes. (2017) Translational challenges of immunotoxicity assessments. Current Opinion in Toxicology 4, pages 35-42.
Crossref
Crossref
Kumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, Pei-Ran Ho, Dan Mikol, Jacob Elkins, Meena Subramanyam & Ivan Nestorov. (2017) Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis. Journal of Pharmacokinetics and Pharmacodynamics 44:3, pages 263-275.
Crossref
Crossref
Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta & Mitchell S V Elkind. (2017) Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 16:3, pages 217-226.
Crossref
Crossref
Thomas H. MasseyRachel SmithShaheena SadiqChristopher OvertonOwen R. Pearson. (2017) Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient. Neurology 88:7, pages 711-713.
Crossref
Crossref
Marco Cosentino, Natasa Kustrimovic & Franca Marino. 2017. Neuroimmune Pharmacology. Neuroimmune Pharmacology
395
406
.
Chris Eckstein. 2017. Case Studies in Multiple Sclerosis. Case Studies in Multiple Sclerosis
43
49
.
Tjalf Ziemssen, Achim Gass, Jens Wuerfel, Antonios Bayas, Björn Tackenberg, Volker Limmroth, Ralf Linker, Mathias Mäurer, Judith Haas, Martin Stangel, Matthias Meergans, Olof Harlin & Hans-Peter Hartung. (2016) Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. BMC Neurology 16:1.
Crossref
Crossref
GK Raju, K Gurumurthi & R Domike. (2016) Benefit-Risk Analysis for Decision-Making: An Approach. Clinical Pharmacology & Therapeutics 100:6, pages 654-671.
Crossref
Crossref
Tatiana Plavina, Edward J. Fox, Nisha Lucas, Kumar Kandadi Muralidharan & Daniel Mikol. (2016) A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis. The Journal of Clinical Pharmacology 56:10, pages 1254-1262.
Crossref
Crossref
Bianca Weinstock-Guttman, Jesper Hagemeier, Katelyn S Kavak, Vasu Saini, Kara Patrick, Deepa P Ramasamy, Muhammad Nadeem, Ellen Carl, David Hojnacki & Robert Zivadinov. (2016) Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery & Psychiatry 87:9, pages 937-943.
Crossref
Crossref
L Zhovtis Ryerson, T C Frohman, J Foley, I Kister, B Weinstock-Guttman, C Tornatore, K Pandey, S Donnelly, S Pawate, R Bomprezzi, D Smith, C Kolb, S Qureshi, D Okuda, J Kalina, Z Rimler, R Green, N Monson, T Hoyt, M Bradshaw, J Fallon, E Chamot, M Bucello, S Beh, G Cutter, E Major, J Herbert & E M Frohman. (2016) Extended interval dosing of natalizumab in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 87:8, pages 885-889.
Crossref
Crossref
Christopher Eckstein & M. Tariq Bhatti. (2016) Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. Survey of Ophthalmology 61:3, pages 318-332.
Crossref
Crossref
Zbyšek Pavelek, Jan Krejsek & Martin Vališ. (2016) Role of T and B cells in pathogenesis of multiple sclerosis. Neurologie pro praxi 17:2, pages 100-103.
Crossref
Crossref
Heinz Wiendl, Helmut Butzkueven, Ludwig Kappos, Maria Trojano, Fabio Pellegrini, Dominic Paes, Annie Zhang & Shibeshih Belachew. (2016) Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLOS ONE 11:1, pages e0144834.
Crossref
Crossref
M. V. Davydovskaya, N. V. Khachanova, E. P. Evdoshenko, I. N. Pronin, A. N. Boiko, M. N. Zakharova, V. M. Alifirova, E. A. Turova, N. A. Malkova, S. A. Sivertseva, L. A. Tsukurova, A. A. Skoromets & I. Yu. Solodun. (2016) Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 116:10. Vyp. 2, pages 79.
Crossref
Crossref
Massimiliano Castellazzi, Tiziana Bellini, Alessandro Trentini, Serena Delbue, Francesca Elia, Matteo Gastaldi, Diego Franciotta, Roberto Bergamaschi, Maria Cristina Manfrinato, Carlo Alberto Volta, Enrico Granieri & Enrico Fainardi. (2016) Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. Disease Markers 2016, pages 1-7.
Crossref
Crossref
J. Nicholas Brenton & Brenda L. Banwell. (2015) Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics 13:1, pages 84-95.
Crossref
Crossref
Michela Spadaro, Marzia Caldano, Fabiana Marnetto, Alessandra Lugaresi & Antonio Bertolotto. (2015) Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. Journal of Neuroinflammation 12:1.
Crossref
Crossref
N. Voloshyna, E. Havrdová, M. Hutchinson, T. Nehrych, X. You, S. Belachew, C. Hotermans & D. Paes. (2014)
Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective
TIMER
study and a retrospective analysis of
AFFIRM
. European Journal of Neurology 22:3, pages 570-577.
Crossref
Crossref
Ioannis Mitroulis, Vasileia I. Alexaki, Ioannis Kourtzelis, Athanassios Ziogas, George Hajishengallis & Triantafyllos Chavakis. (2015) Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacology & Therapeutics 147, pages 123-135.
Crossref
Crossref
H. Butzkueven, L. Kappos, F. Pellegrini, M. Trojano, H. Wiendl, R. N. Patel, A. Zhang, C. Hotermans & S. Belachew. (2014) Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery & Psychiatry 85:11, pages 1190-1197.
Crossref
Crossref
Alireza Minagar. (2014) Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 6:4, pages 1-117.
Crossref
Crossref
A. H. Cross & R. T. Naismith. (2014) Established and novel disease-modifying treatments in multiple sclerosis. Journal of Internal Medicine 275:4, pages 350-363.
Crossref
Crossref
Maria Meira, Claudia Sievers, Francine Hoffmann, Maria Rasenack, Jens Kuhle, Tobias Derfuss, Ludwig Kappos & Raija L. P. Lindberg. (2014)
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4
+
T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
. Journal of Immunology Research 2014, pages 1-11.
Crossref
Crossref
Bianca Weinstock-Guttman, Murali Ramanathan & Robert ZivadinovPer Soelberg Sørensen. 2013. Personalized Management of Multiple Sclerosis. Personalized Management of Multiple Sclerosis
64
87
.
Ludwig Kappos, Paul W. O’Connor, Christopher H. Polman, Patrick Vermersch, Heinz Wiendl, Amy Pace, Annie Zhang & Christophe Hotermans. (2013) Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. Journal of Neurology 260:5, pages 1388-1395.
Crossref
Crossref
Christian Wolf, Jagdev Sidhu, Christian Otoul, Dexter L. Morris, Jennifer Cnops, Jorg Taubel & Barbara Bennett. (2013) Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. PLoS ONE 8:3, pages e58438.
Crossref
Crossref
Hisanori Yagami, Hiroshi Kato, Kanta Tsumoto & Masahiro Tomita. (2013) Monoclonal antibodies based on hybridoma technology. Pharmaceutical Patent Analyst 2:2, pages 249-263.
Crossref
Crossref
Alireza Minagar. (2013) Current and Future Therapies for Multiple Sclerosis. Scientifica 2013, pages 1-11.
Crossref
Crossref
Daniel Ontaneda & Daniela Di Capua. (2012)
Benefits
versus
risks of latest therapies in multiple sclerosis: a perspective review
. Therapeutic Advances in Drug Safety 3:6, pages 291-303.
Crossref
Crossref
Franz Fazekas. (2012) Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert GroupFingolimod im Behandlungsalgorithmus der schubförmigen Multiplen Sklerose: Eine Stellungnahme der mittel- und osteuropäischen MS ExpertInnengruppe. Wiener Medizinische Wochenschrift 162:15-16, pages 354-366.
Crossref
Crossref
Lakshmi Devi Kandagaddala, Min-Jung Kang, Md. Mamunul Haque, Hye-Yeon Im, Ji-Eun Seo, Bong Chul Chung, Byung Hwa Jung, Tucker A. Patterson & Oh-Seung Kwon. (2012) In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice. Journal of the Neurological Sciences 318:1-2, pages 36-44.
Crossref
Crossref
Alfred W. Sandrock & Richard A. Rudick. 2012. Translational Neuroscience. Translational Neuroscience
178
196
.
Per Soelberg SørensenAntonio Bertolotto, Gilles EdanGavin Giovannoni, Ralf GoldEva HavrdovaLudwig Kappos, Bernd C KieseierXavier Montalban & Tomas Olsson. (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal 18:2, pages 143-152.
Crossref
Crossref
Henrik Gensicke, David Leppert, Özgür Yaldizli, Raija L.P. Lindberg, Matthias Mehling, Ludwig Kappos & Jens Kuhle. (2012) Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs 26:1, pages 11-37.
Crossref
Crossref
Chris H. Polman, Joep Killestein & Richard A. Rudick. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
330
343
.
. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
300
582
.
Per Soelberg Sørensen. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
287
299
.
. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
56
299
.
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj & Ian Galea. (2011) Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Aaron Boster, Mary Pat Bartoszek, Colleen O’Connell, David Pitt & Michael Racke. (2011) Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders 4:5, pages 319-332.
Crossref
Crossref
Per Soelberg SørensenPoul Erik Hyldgaard JensenAiden HaghikiaMalin LundkvistChristian VedelerFinn SellebjergNils Koch-HenriksenAnna Fogdell-HahnKjell-Morten MyhrJan HillertRalf Gold. (2011) Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis Journal 17:9, pages 1074-1078.
Crossref
Crossref
Martin Duddy, Aiden Haghikia, Eleonora Cocco, Christian Eggers, Jelena Drulovic, Olga Carmona, Helene Zéphir & Ralf Gold. (2011) Managing MS in a changing treatment landscape. Journal of Neurology 258:5, pages 728-739.
Crossref
Crossref
Flavia Mattioli, C. Stampatori & R. Capra. (2010) The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurological Sciences 32:1, pages 83-88.
Crossref
Crossref
Eileen M. O’Connor & Rae Ann Maxwell. 2011. Neuroinflammation. Neuroinflammation
167
191
.
F. Mattioli, C. Stampatori, F. Bellomi & R. Capra. (2010) Natalizumab efficacy on cognitive impairment in MS. Neurological Sciences 31:S3, pages 321-323.
Crossref
Crossref
Joseph R. Berger. (2010) Progressive Multifocal Leukoencephalopathy and Newer Biological Agents. Drug Safety 33:11, pages 969-983.
Crossref
Crossref
D.T. Selewski, G.V. Shah, B.M. Segal, P.A. Rajdev & S.K. Mukherji. (2010) Natalizumab (Tysabri). American Journal of Neuroradiology 31:9, pages 1588-1590.
Crossref
Crossref
Reza Vosoughi & Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, pages 365-385.
Crossref
Crossref
Zhiqiang An. (2010) Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases. Protein & Cell 1:4, pages 319-330.
Crossref
Crossref
Bibiana BielekovaBrenda L. Becker. (2010) Monoclonal antibodies in MS. Neurology 74:1_supplement_1.
Crossref
Crossref
Patricia K CoyleJohn F FoleyEdward J FoxDouglas R JefferyFrederick E MunschauerIiiIiiCarlo Tornatore. (2009) Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Multiple Sclerosis Journal 15:4_suppl, pages 26-36.
Crossref
Crossref
Patricia K CoyleDouglas R Jeffery. (2009) Clinical efficacy and benefit of natalizumab. Multiple Sclerosis Journal 15:4_suppl, pages 7-15.
Crossref
Crossref
Ningyan Zhang, Brent R. Williams, Ping Lu, Zhiqiang An & Chen-Ni Chin. 2009. Therapeutic Monoclonal Antibodies. Therapeutic Monoclonal Antibodies
711
762
.
Michael Thorne, Craig S. Moore & George S. Robertson. (2009) Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice. Journal of Neuroimmunology 211:1-2, pages 92-100.
Crossref
Crossref
Ö. Yaldizli, P. Baumberger & N. Putzki. (2009) Natalizumab et nævus atypiques : commentaires sur la note de pharmacovigilance de J.-L. Schmutz et al.. Annales de Dermatologie et de Vénéréologie 136:5, pages 450-451.
Crossref
Crossref
A. D. GoodmanH. RossmanA. Bar-OrA. MillerD. H. MillerK. SchmiererF. LublinO. KhanN. M. BormannM. YangM. A. PanzaraA. W. Sandrock. (2009) GLANCE. Neurology 72:9, pages 806-812.
Crossref
Crossref
Özgür YaldizliNorman Putzki. (2009) Review: Natalizumab in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders 2:2, pages 115-128.
Crossref
Crossref
B. O. KhatriS. ManG. GiovannoniA. P. KooJ-C LeeB. TuckyF. LynnS. JurgensenJ. WoodworthS. GoelzP. W. DudaM. A. PanzaraR. M. RansohoffR. J. Fox. (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72:5, pages 402-409.
Crossref
Crossref
P. S. Rommer, O. Stüve, R. Goertsches, E. Mix & U. K. Zettl. (2008) Monoclonal antibodies in the therapy of multiple sclerosis. Journal of Neurology 255:S6, pages 28-35.
Crossref
Crossref
Meena Subramanyam. 2008. Immunogenicity of Biopharmaceuticals. Immunogenicity of Biopharmaceuticals
173
187
.
Kenneth P. Johnson. (2007) Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis. The Neurologist 13:4, pages 182-187.
Crossref
Crossref
P. Vermersch & H. Zéphir. (2007) Immunosuppression par anticorps monoclonaux dans la sclérose en plaques. Revue Neurologique 163:6-7, pages 682-687.
Crossref
Crossref
Ludwig Kappos, David Bates, Hans-Peter Hartung, Eva Havrdova, David Miller, Chris H Polman, Mads Ravnborg, Stephen L Hauser, Richard A Rudick, Howard L Weiner, Paul W O'Connor, John King, Ernst Wilhelm Radue, Tarek Yousry, Eugene O Major & David B Clifford. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. The Lancet Neurology 6:5, pages 431-441.
Crossref
Crossref
Bilal A. Choudry & Jane W. Chan. (2016) An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20:2, pages 167-180.
Crossref
Crossref
Sebastian Schimrigk & Ralf Gold. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
941
950
.
Christiane Kummer & Mark H. Ginsberg. (2006) New approaches to blockade of α4-integrins, proven therapeutic targets in chronic inflammation. Biochemical Pharmacology 72:11, pages 1460-1468.
Crossref
Crossref
Russell E Bartt. (2006) Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Current Opinion in Neurology 19:4, pages 341-349.
Crossref
Crossref
. (2006) Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine 354:22, pages 2387-2389.
Crossref
Crossref
Adil Javed & Anthony T. Reder. (2006) Therapeutic role of beta-interferons in multiple sclerosis. Pharmacology & Therapeutics 110:1, pages 35-56.
Crossref
Crossref
Kendra A Keeley, Michael P Rivey & Douglas R Allington. (2005) Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. Annals of Pharmacotherapy 39:11, pages 1833-1843.
Crossref
Crossref
Hans-Peter Hartung, Bernd C. Kieseier & Bernhard Hemmer. (2005) Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. Journal of Neurology 252:S5, pages v30-v37.
Crossref
Crossref
Joseph R. Berger & Igor J. Koralnik. (2005) Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences. New England Journal of Medicine 353:4, pages 414-416.
Crossref
Crossref
Jack S. Burks. (2005) A Practical Approach to Immunomodulatory Therapy for Multiple Sclerosis. Physical Medicine and Rehabilitation Clinics of North America 16:2, pages 449-466.
Crossref
Crossref